Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy

Guangdong Provincial People's Hospital170 enrolled

Overview

This is a prospective randomized controlled, open-labeled study to identify the efficacy of probucol in combination with valsartan in patients with Diabetes nephropathy. The reduction of urinary albumin or proteinuria will be the primary outcome studied. The expected study duration will be 48 weeks.

a prospective randomized controlled, open-labeled study in patients with Diabetes nephropathy * Arm 1: Valsartan + Probucol Valsartan (160mg/day) + Probucol (750mg/day) * Arm 2: Valsartan + Placebo Valsartan (160mg/day) + Placebo

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

170

Conditions

Type 2 Diabetes Mellitus Nephropathy

Interventions

ValsartanDRUG

Valsartan (160mg/day)

PlaceboDRUG

Placebo

ProbucolDRUG

Probucol (750mg/day)

Eligibility

Sex: ALLMin age: 30 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 Diabetes nephropathy * Urinary albumin excretion 1-3g/24hours * Serum creatinine \< 3mg/dl Exclusion Criteria: * Type 1 diabetes mellitus * Renal diseases other than type 2 Diabetes nephropathy * Renal artery stenosis * Severe heart diseases * Tuberculosis

Locations (1)

Guangdong General Hospital

Guangzhou, Guangdong, China

Outcomes

Primary Outcomes

urinary albumin excretion or proteinuria at week 48

Time frame: 48 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.